Table 3. DNA hypermethylation analysis in relation to tumour histology.
|
Diagnosis |
|||
|---|---|---|---|
| SCC (n=81), % | AC (n=92), % | P-value | |
|
RASSF1A | |||
| Negative | 41 | 59 | 0.056 |
| Positive | 56 | 44 | |
|
APC | |||
| Negative | 52 | 48 | 0.23 |
| Positive | 43 | 57 | |
|
CYGB | |||
| Negative | 52 | 48 | 0.15 |
| Positive | 41 | 59 | |
|
3OST2 | |||
| Negative | 52 | 48 | 0.20 |
| Positive | 42 | 58 | |
|
PRDM14 | |||
| Negative | 55 | 45 | 0.11 |
| Positive | 42 | 58 | |
|
FAM19A4 | |||
| Negative | 45 | 55 | 0.84 |
| Positive | 47 | 53 | |
|
PHACTR3 | |||
| Negative | 62 | 38 | 0.001 |
| Positive | 36 | 64 | |
Abbreviations: SCC=squamous cell carcinoma; AC=adenocarcinoma.
Cutoff for positive hypermethylation is based on Youden's J index of biomarkers.